Q-omics provides the consensus-scored HPCAL4 profile across patient tissues and cancer cell-line models. HPCAL4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, HPCAL4 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, HPCAL4 RNA expression shows 16,374 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where HPCAL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HPCAL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HPCAL4 survival associations across molecular data types. HPCAL4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HPCAL4 RNA expression–survival associations across cancer types. High HPCAL4 expression shows unfavorable associations in UCEC and ACC, but favorable associations in LUAD, THCA, LGG and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for HPCAL4 RNA expression.
This table summarizes HPCAL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for HPCAL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HPCAL4 shows lower tumor expression in KIRC, KIRP, KICH, STAD and LUSC and higher tumor expression in THCA. The KIRC box plot shows higher HPCAL4 RNA expression in normal versus tumor tissue (log2 FC = −2.693, t-test p < 0.001).
This table shows molecular features associated with HPCAL4 in patient tissues and cancer cell lines. In patient samples, HPCAL4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HPCAL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
